Adam Walsh
Stock Analyst at Roth MKM
(3.22)
# 2,492
Out of 5,060 analysts
144
Total ratings
40.7%
Success rate
3.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Reiterated: Buy | $12 | $1.19 | +908.40% | 13 | Oct 6, 2026 | |
| OSTX OS Therapies | Reiterated: Buy | $7 | $1.32 | +430.30% | 6 | Oct 6, 2026 | |
| VTVT vTv Therapeutics | Reiterated: Buy | $58 | $26.45 | +119.32% | 7 | Oct 6, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $41 | $10.35 | +296.14% | 10 | Sep 24, 2026 | |
| INSM Insmed | Reiterated: Buy | $212 → $198 | $96.27 | +105.67% | 23 | Sep 15, 2026 | |
| BIOA BioAge Labs | Reiterated: Buy | $25 | $4.84 | +416.53% | 5 | Sep 9, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterated: Buy | $70 → $82 | $14.54 | n/a | 19 | May 18, 2020 | |
| ASND Ascendis Pharma | Reiterated: Buy | $81 → $171 | $225.24 | n/a | 3 | Apr 20, 2020 | |
| LKFT Lakefront Biotherapeutics NV | Reiterated: Buy | $298 | $29.96 | n/a | 9 | Apr 8, 2020 | |
| CORT Corcept Therapeutics | Reiterated: Hold | n/a | $110.16 | n/a | 8 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $71 | $4.85 | n/a | 2 | Nov 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 → $25 | $0.7001 | n/a | 4 | Jun 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $11 → $17 | $128.75 | n/a | 3 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $129 → $182 | $499.74 | n/a | 13 | Jul 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $107 | $54.68 | n/a | 5 | Mar 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $221.37 | $8.92 | n/a | 1 | Nov 30, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $231.83 | n/a | 11 | Jun 24, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 → $30 | $17.10 | n/a | 2 | May 20, 2015 |
Equillium
Oct 6, 2026
Reiterated: Buy
Price Target: $12
Current: $1.19
Upside: +908.40%
OS Therapies
Oct 6, 2026
Reiterated: Buy
Price Target: $7
Current: $1.32
Upside: +430.30%
vTv Therapeutics
Oct 6, 2026
Reiterated: Buy
Price Target: $58
Current: $26.45
Upside: +119.32%
Arcturus Therapeutics Holdings
Sep 24, 2026
Reiterated: Buy
Price Target: $41
Current: $10.35
Upside: +296.14%
Insmed
Sep 15, 2026
Reiterated: Buy
Price Target: $212 → $198
Current: $96.27
Upside: +105.67%
BioAge Labs
Sep 9, 2026
Reiterated: Buy
Price Target: $25
Current: $4.84
Upside: +416.53%
Ultragenyx Pharmaceutical
May 18, 2020
Reiterated: Buy
Price Target: $70 → $82
Current: $14.54
Upside: n/a
Ascendis Pharma
Apr 20, 2020
Reiterated: Buy
Price Target: $81 → $171
Current: $225.24
Upside: n/a
Lakefront Biotherapeutics NV
Apr 8, 2020
Reiterated: Buy
Price Target: $298
Current: $29.96
Upside: n/a
Corcept Therapeutics
Feb 10, 2020
Reiterated: Hold
Price Target: n/a
Current: $110.16
Upside: n/a
Nov 12, 2019
Reiterated: Buy
Price Target: $71
Current: $4.85
Upside: n/a
Jun 25, 2019
Reiterated: Buy
Price Target: $36 → $25
Current: $0.7001
Upside: n/a
May 8, 2019
Upgraded: Buy
Price Target: $11 → $17
Current: $128.75
Upside: n/a
Jul 18, 2017
Rated: Buy
Price Target: $129 → $182
Current: $499.74
Upside: n/a
Mar 3, 2016
Reiterated: Buy
Price Target: $105 → $107
Current: $54.68
Upside: n/a
Nov 30, 2015
Initiated Coverage: Buy
Price Target: $221.37
Current: $8.92
Upside: n/a
Jun 24, 2015
Reiterated: Buy
Price Target: $160
Current: $231.83
Upside: n/a
May 20, 2015
Upgraded: Buy
Price Target: $16 → $30
Current: $17.10
Upside: n/a